Group 1 - The Rosen Law Firm is reminding purchasers of Applied Therapeutics, Inc. securities of the lead plaintiff deadline on February 18, 2025, for a class action lawsuit [1] - Investors who purchased securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Applied Therapeutics made false and misleading statements regarding its clinical trial protocols, which created a risk of FDA rejection of trial data [5] - The firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the legal field [4]

Core Viewpoint - A securities class action lawsuit has been filed against Applied Therapeutics, Inc. for alleged misconduct related to its drug candidate, govorestat, during the Class Period from January 3, 2024, to December 2, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York [1]. - The lead plaintiff deadline for investors is set for February 18, 2025 [1][4]. - The complaint alleges that Applied Therapeutics made false or misleading statements and failed to disclose non-compliance with trial protocols, risking FDA rejection of trial data [3]. Group 2: Investor Information - Investors who suffered losses can seek to be appointed as lead plaintiffs or remain absent class members [4]. - The lead plaintiff represents the interests of all class members and selects counsel for the litigation [4]. - Kessler Topaz Meltzer & Check, LLP encourages affected investors to contact them for more information [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Applied Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Applied Therapeutics January 3, 2024 and December 2, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 7, ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"), of the important February 18, 2025 lead plaintiff deadline.So what: If you purchased Applied Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT). Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=127301&from=3 CLASS P ...

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=127263&from=4CLASS PERIOD: Ja ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Applied Therapeu ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=126267&from=4CLASS PERIOD: Ja ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Applied Therapeutics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Applied Therapeutics January 3, 2024 and December 2, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 2, 2025 /PRNewswire/ ...